Technical analyst Ramesh Arora has maintained 'buy' rating on Lupin Limited stock with a target of Rs 474.

According to analyst, the investors can purchase the stock with a stop loss of Rs 452.

As per reports, Lupin is the best long term scrip with quite a few short term rallies and it has truly been one of the bettor performers.

The stock of the company, on December 28, closed at Rs 460.05 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 519.80 and a low of Rs 277 on BSE.

Current EPS & P/E ratio stood at 17.78 and 26.41 respectively.

Undiscouraged by USFDA's no to a previous appeal, Lupin Pharma has requested it to stop receipt of any generic drug application of anti-cholesterol drug Antara, if the generic product doesn't contain the similar quantity.

For the three month period ended September 30, Lupin said that its consolidated net profit surged 34.13% to Rs 215.02 crore on account of healthy sales across all market segments, headed by the US and Japan.

The company recorded a net profit of Rs 160.30 crore during the corresponding quarter of 2009.

The company's net sales remained at Rs 1,405.05 crore for the said quarter as against Rs 1,114.69 crore during the same period last fiscal.

Lupin Limited MD Kamal K Sharma stated, "This quarter's business performance was fuelled by a strong business performance in the US and Japan, solid domestic growth and increased activity in all key pharmerging (emerging pharma) markets, including South Africa and Australia."